ReviewFrontiers in pharmacology2026
Nanomaterial-mediated modulation of gut microbiota for precision diagnosis and treatment of colorectal cancer: a comprehensive review.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The critical role of gut microbiota in the initiation and progression of colorectal cancer (CRC) has garnered widespread recognition. Leveraging their precise targeting capabilities and programmable properties, nanomaterials are emerging as novel strategy for modulating the interplay between microbiota and tumors. This comprehensive review examines functional nanomaterials-including nanoparticles, nanocapsules, and nanoreactors-and elucidates their mechanisms of action in remodeling the CRC immune microenvironment and potentiating responses to chemoradiotherapy and immunotherapy through microbiota modulation. We further highlight the synergistic value of nanomaterials in multimodal CRC theranostics: (i) serving as microbiota modulation carriers for integrated diagnosis and therapy; (ii) activating systemic anti-tumor immunity via the gut-microbiota-immune axis; and (iii) targeting CRC drug resistance and metastasis. Finally, we discuss challenges associated with clinical translation, including assessment of long-term nanomaterial biosafety and optimization of personalized microbiota intervention protocols. This review provides theoretical foundations and technical insights for developing precision diagnostic and therapeutic strategies for CRC based on nano-microbiota interactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.